Month: April 2023

AT A GLANCE… GLP-1 drugs continue to hit the headlines, with United Health Group CEO Andrew Witty weighing in on their benefit and usage. Pregnancy risks of GLP-1 meds – very low likelihood, though currently unknown beyond animal studies. Teledoc strides into GLP-1 space; and Ro founder Zachariah Reitano publishes a long piece on the scientific basis of obesity management with respect to GLP-1 medications. Bariatric surgery reviewed for treatment

AT A GLANCE… Calibrate, a telehealth GLP-1 prescription machine, reports an 18% reduction in workforce, with a move to employer-based contracts. Legacy weight loss companies focused upon behavior change, counting calories and low-carb diets are in a quandary whether to embrace anti-obesity medications. Prediabetes currently affects 1 in 3 adult Americans and is projected to impact over one billion people across the globe by 2045. More

I wish everyone a Happy Easter if you celebrate and happy weekend if you do not :) AT A GLANCE… Beyond BMI – a high-profile academic committee gets together this week to debate and define the role of BMI as a measure of obesity and health. The U.S. military is struggling with recruitment and lost workdays of their soldiers due to challenges with managing obesity. Two

AT A GLANCE… New data on Rybelsus oral GLP-1 medication from Novo Nordisk, in addition to newbie GLP-1/GIP medication [akin to Mounjaro from Eli Lilly] from Viking Therapeutics, code-named VK2735. The anti-obesity medication market is hotting up, with aligned stock price increases across the board. Are anti-obesity medications the next frontier in saving millions of lives across the globe, akin to medications for sufferers